A similar trend was identified with respect to aggression, with triple-negative breast cancer (TNBC) and HER2-positive tumors, i.e., clinically more aggressive tumors, having higher scores compared to ER-positive HER2-negative subtypes. This evidence concerns the gene ESR1 and triple-negative breast carcinoma.